PTC Therapeutics (NASDAQ:PTCT) has been given a consensus recommendation of “Hold” by the eleven research firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $27.00.
Several brokerages have recently weighed in on PTCT. Barclays downgraded PTC Therapeutics from an “equal weight” rating to an “underweight” rating and increased their price target for the stock from $24.00 to $26.00 in a report on Tuesday, April 3rd. Zacks Investment Research upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Saturday, March 10th. William Blair reiterated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, March 7th. Citigroup increased their price target on PTC Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $28.00 price target on shares of PTC Therapeutics in a report on Tuesday, January 30th.
PTCT stock traded down $0.27 during midday trading on Friday, reaching $25.83. 30,356 shares of the company traded hands, compared to its average volume of 996,294. PTC Therapeutics has a 52-week low of $10.65 and a 52-week high of $33.22. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.90 and a current ratio of 3.04.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.17. PTC Therapeutics had a negative return on equity of 50.75% and a negative net margin of 40.64%. The business had revenue of $78.00 million for the quarter, compared to the consensus estimate of $78.59 million. During the same period in the prior year, the business posted ($0.78) earnings per share. The company’s quarterly revenue was up 209.5% compared to the same quarter last year. sell-side analysts forecast that PTC Therapeutics will post -1.55 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP increased its holdings in PTC Therapeutics by 18.2% during the 4th quarter. RTW Investments LP now owns 4,130,115 shares of the biopharmaceutical company’s stock worth $68,890,000 after purchasing an additional 634,972 shares during the period. Spark Investment Management LLC increased its holdings in PTC Therapeutics by 44.7% during the 4th quarter. Spark Investment Management LLC now owns 1,037,200 shares of the biopharmaceutical company’s stock worth $17,300,000 after purchasing an additional 320,200 shares during the period. Goldman Sachs Group Inc. increased its holdings in PTC Therapeutics by 182.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 796,518 shares of the biopharmaceutical company’s stock worth $13,286,000 after purchasing an additional 514,068 shares during the period. J. Goldman & Co LP increased its holdings in PTC Therapeutics by 3,516.8% during the 4th quarter. J. Goldman & Co LP now owns 653,284 shares of the biopharmaceutical company’s stock worth $10,897,000 after purchasing an additional 672,404 shares during the period. Finally, Millennium Management LLC increased its holdings in PTC Therapeutics by 113.0% during the 4th quarter. Millennium Management LLC now owns 555,205 shares of the biopharmaceutical company’s stock worth $9,261,000 after purchasing an additional 294,572 shares during the period. Institutional investors own 83.18% of the company’s stock.
WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/20/ptc-therapeutics-ptct-given-consensus-recommendation-of-hold-by-brokerages.html.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.